Identifying drug target candidates to treat pediatric rhabdomyosarcoma tumors
In a new report in Science Advances, Sara G. Danielli and an international, interdisciplinary team of scientists at the department of Oncology and Children's Research, Stem Cell Biology, and Translational Research in Child and Adolescent Cancer, in the U.S., Switzerland, France, Germany and Spain, combined a myriad of biological methods to understand the etiology and cellular basis of RMS oncogenesis.
Comments